Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept Injection (ELYSIAN)

NCT02630277 is registered in ClinicalTrials.gov with Valley Retina Institute as lead sponsor.

NCT NCT02630277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02630277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept Injection (ELYSIAN)
Lead sponsor
Valley Retina Institute
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2016
Completion date
June 30, 2017
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

proliferative diabetic retinopathy